Castle Biosciences, Inc. (CSTL) stock is experiencing a significant pre-market plunge of 6.13% on Tuesday following the release of its first-quarter 2025 earnings report. The company's results fell short of analysts' expectations, disappointing investors and triggering a sell-off in early trading.
For the quarter ended March 31, Castle Biosciences reported a quarterly adjusted loss of 20 cents per share, significantly wider than the mean expectation of a 7-cent loss per share from nine analysts. This result also marks a deterioration from the same quarter last year when the company reported a loss of 9 cents per share. Despite the earnings miss, revenue rose 20.6% to $87.99 million, surpassing analysts' expectations of $80.34 million.
The medical diagnostics company's reported EPS for the quarter showed a loss of 90 cents, resulting in a quarterly loss of $25.85 million. This performance comes amid a challenging year for Castle Biosciences, with its shares already down 27.4% year-to-date before this latest setback. Despite the negative earnings surprise, Wall Street maintains a bullish outlook on the stock, with a consensus "strong buy" rating and a median 12-month price target of $40.00.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.